Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03385486Phase 1Unknown

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

Role: lead

NCT04709458Phase 1Unknown

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Role: lead

NCT04640246Phase 1Unknown

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Role: lead

NCT02860559Phase 1Unknown

Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency

Role: lead

All 4 trials loaded